EZETIMIBE\SIMVASTATIN: 1,960 Adverse Event Reports & Safety Profile
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
1,960
Total FAERS Reports
127 (6.5%)
Deaths Reported
634
Hospitalizations
1,960
As Primary/Secondary Suspect
153
Life-Threatening
98
Disabilities
First Report: 1980 · Latest Report: 20250721
What Are the Most Common EZETIMIBE\SIMVASTATIN Side Effects?
#1 Most Reported
Myalgia
244 reports (12.4%)
#2 Most Reported
Acute kidney injury
132 reports (6.7%)
#3 Most Reported
Rhabdomyolysis
113 reports (5.8%)
All EZETIMIBE\SIMVASTATIN Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Myalgia | 244 | 12.5% | 0 | 25 |
| Acute kidney injury | 132 | 6.7% | 16 | 106 |
| Rhabdomyolysis | 113 | 5.8% | 6 | 75 |
| Drug hypersensitivity | 112 | 5.7% | 0 | 2 |
| Arthralgia | 89 | 4.5% | 0 | 14 |
| Diarrhoea | 71 | 3.6% | 5 | 34 |
| Muscle spasms | 70 | 3.6% | 0 | 7 |
| No adverse event | 68 | 3.5% | 0 | 4 |
| Fatigue | 66 | 3.4% | 0 | 20 |
| Rash | 54 | 2.8% | 0 | 10 |
| Off label use | 49 | 2.5% | 0 | 19 |
| Blood creatine phosphokinase increased | 47 | 2.4% | 0 | 8 |
| Pain in extremity | 47 | 2.4% | 0 | 10 |
| Depression | 46 | 2.4% | 2 | 12 |
| Nausea | 46 | 2.4% | 0 | 11 |
| Dyspnoea | 45 | 2.3% | 0 | 21 |
| Lactic acidosis | 44 | 2.2% | 14 | 19 |
| Pruritus | 44 | 2.2% | 5 | 12 |
| Drug ineffective | 43 | 2.2% | 0 | 8 |
| Muscular weakness | 41 | 2.1% | 0 | 6 |
Who Reports EZETIMIBE\SIMVASTATIN Side Effects? Age & Gender Data
Gender: 49.2% female, 50.8% male. Average age: 65.3 years. Most reports from: US. View detailed demographics →
Is EZETIMIBE\SIMVASTATIN Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2000 | 3 | 0 | 0 |
| 2001 | 3 | 0 | 2 |
| 2002 | 5 | 0 | 0 |
| 2003 | 7 | 0 | 0 |
| 2004 | 2 | 0 | 0 |
| 2005 | 10 | 1 | 5 |
| 2006 | 12 | 1 | 3 |
| 2007 | 19 | 0 | 10 |
| 2008 | 26 | 2 | 8 |
| 2009 | 22 | 1 | 12 |
| 2010 | 27 | 1 | 13 |
| 2011 | 33 | 3 | 12 |
| 2012 | 36 | 1 | 12 |
| 2013 | 46 | 4 | 14 |
| 2014 | 97 | 6 | 35 |
| 2015 | 160 | 17 | 81 |
| 2016 | 91 | 4 | 40 |
| 2017 | 121 | 5 | 37 |
| 2018 | 123 | 27 | 33 |
| 2019 | 103 | 6 | 57 |
| 2020 | 66 | 2 | 25 |
| 2021 | 66 | 8 | 15 |
| 2022 | 77 | 0 | 54 |
| 2023 | 56 | 0 | 23 |
| 2024 | 20 | 3 | 7 |
| 2025 | 7 | 0 | 3 |
What Is EZETIMIBE\SIMVASTATIN Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 374 |
| Dyslipidaemia | 302 |
| Hypercholesterolaemia | 204 |
| Blood cholesterol increased | 134 |
| Hyperlipidaemia | 68 |
| Coronary artery disease | 50 |
| Blood cholesterol abnormal | 48 |
| Acute coronary syndrome | 47 |
| Type iia hyperlipidaemia | 40 |
| Blood cholesterol | 37 |
EZETIMIBE\SIMVASTATIN vs Alternatives: Which Is Safer?
EZETIMIBE\SIMVASTATIN vs EZOGABINE
EZETIMIBE\SIMVASTATIN vs FACTOR XIII CONCENTRATE
EZETIMIBE\SIMVASTATIN vs FAM-TRASTUZUMAB DERUXTECAN-NXKI
EZETIMIBE\SIMVASTATIN vs FAMCICLOVIR
EZETIMIBE\SIMVASTATIN vs FAMOTIDINE
EZETIMIBE\SIMVASTATIN vs FAMOTIDINE\IBUPROFEN
EZETIMIBE\SIMVASTATIN vs FARICIMAB
EZETIMIBE\SIMVASTATIN vs FARICIMAB-SVOA
EZETIMIBE\SIMVASTATIN vs FARICIMAB\FARICIMAB-SVOA
EZETIMIBE\SIMVASTATIN vs FASLODEX
Official FDA Label for EZETIMIBE\SIMVASTATIN
Official prescribing information from the FDA-approved drug label.